The purpose of the Depression Clinical Practice Guideline is to assist the interdisciplinary care team through the process of recognition, diagnosis, treatment, and monitoring of depression in the long-term care facility resident. It includes an expanded section on pharmacology, many tables providing strategies to assist in diagnosing and managing depression, and screening tools to assist in recognition of depression. Pharmacotherapy is one component of a multifaceted approach to the management of depression in the long-term care setting. The Pharmacotherapy Companion to the depression clinical practice guideline focuses on the pharmacotherapy of depression. The goals of this companion are to: promote effective treatment of depression in the long-term care facility by helping practitioners select the most appropriate antidepressant for each patient and to eliminate inappropriate pharmacotherapy; outline a process that facilitates optimal prescribing of pharmacotherapy for depression; provide information to all members of the care team concerning the rationale for and choice of antidepressant medications; assist practitioners and other members of the interdisciplinary team in applying the concept of pharmacoeconomics to evaluation of the outcomes of depression pharmacotherapy; differentiate between remission and response when evaluating the clinical outcomes of depression pharmacotherapy; and discuss adverse drug events related to antidepressant pharmacotherapy, including drug-drug and drug-disease interactions.
11000 Broken Land Parkway, Suite 400 Columbia, MD 21044
P: (410) 740-9743 / (800) 876-2632 - F: (410) 740-4572 - E-mail: email@example.com